- Articles, Books, Databases, etc.
- Research Guides
- Class Support
- Services
- Library Information
- Event & Program Support
![[photo - Margaret Eaton]](../../../images/facultypublications/eaton-margaret-l.jpg)
Margaret Eaton teaches an interdisciplinary course about the bioscience industry, a category that includes biotechnology, pharmaceutical, medical device, genomics, vaccines, and medical diagnostics. Her teaching and case development focuses on the ethical, social, and legal issues that are an inherent feature in the development of these products. To study these issues, Dr. Eaton's classes are comprised of graduate students from the different disciplines that work in these companies - business, medical, bio and chemical engineering, and legal students. The result is a multidisciplinary approach to a full array of business management dilemmas. more...
![[photo - Donald Kennedy]](../../../images/facultypublications/kennedy_100.jpg)
Donald Kennedy is emeritus Bing Professor of Environmental Science and President Emeritus of Stanford University. A former U.S. Food and Drug Administration commissioner, Dr. Kennedy co-chairs the National Academies of Science Project on Science, Technology, and Law and is the editor-in-chief of Science.
more...
Faculty Books:
Innovation in Medical Technology
Innovation in Medical Technology: Ethical Issues and Challenges
by Margaret L. Eaton and Donald Kennedy.
Johns Hopkins University Press, 2007
This thought-provoking study examines the ethical, legal, and social problems that arise with cutting-edge medical technology. Using as examples four powerful and largely unregulated technologies-off-label use of drugs, innovative surgery, assisted reproduction, and neuroimaging-Margaret L. Eaton and Donald Kennedy illustrate the difficult challenges faced by clinicians, researchers, and policy makers who seek to advance the frontiers of medicine safely and responsibly. Supported by medical history and case studies and drawing on reports from dozens of experts, the authors address important practical, ethical, and policy issues. They consider topics such as the responsible introduction of new medical products and services, the importance of patient consent, the extent of the duty to mitigate harm, and the responsibility to facilitate access to new medical therapies. This work's insights into the nature and consequences of medical innovation contribute to the national debate on how best to protect patients while fostering innovation and securing benefits. more...
Selected Reviews
From Journal of the American Medical Association
Reviewer: Richard M. Stillman, MD. 2007;297:2530-2531
"The fundamental question "When can society condone exposing a few people to harm to benefit the many?" was addressed in 1979 through a set of guidelines for ethical human research contained in the Belmont Report and subsequently incorporated into the Code of Federal Regulations (Title 45, Part 46). This so-called Common Rule governs the institutional review board and the consent process in federally funded research.
But medical technology has evolved, and with this evolution have arisen new, formidable ethical dilemmas.
Eighty-seven prominent physicians, researchers, ethicists, journalists, and legal scholars met in May 2003 at the invitation-only Lasker Forum on Ethical Challenges in Biomedical Research and Practice to address some of these issues. Two days of insightful dialogue among those influential scholars inspired Drs Margaret L. Eaton (a forum attendee and Stanford bioethicist) and Donald Kennedy (the forum's co-chair and editor-in-chief of Science) to condense and annotate the forum's explorations. Innovation in Medical Technology is the result of these efforts." more...
From The New England Journal of Medicine
Reviewer: Baruch A. Brody, Ph.D. 2007; 357(14):1456-1457
"The theme of the book is innovation. The authors recognize that innovations can sometimes be appropriately introduced in clinical practice settings, whereas on other occasions they are best introduced in formal research settings. Examples of each scenario are provided in chapters 3 through 6, in four contexts: the off-label use of drugs, surgery, assisted reproduction, and neuroimaging. These examples are also used to establish the point that "the existing binary choice between research and practice is probably too constraining" and that it is best to think of medical innovation as an in-between category that requires some oversight but not the formal institutional review board system. The authors pose several crucial questions in chapter 7: What are the thresholds and models for oversight? What information should be disclosed to patients? Is there a professional duty to learn and to educate other practitioners? Eaton and Kennedy provide guidelines in response to each question." more...
